(1) Department of Medicine, Shiga University of Medical Science, Seta-Tukinowa, Otsu 520-2192, Japan;(2) Division of Mucosal Immunology, Graduate School, Shiga University of Medical Science, Seta-Tukinowa, Otsu 520-2192, Japan;
Abstract:
Background
The formation of antibodies to infliximab (ATIs) is closely associated with the loss of response to infliximab in patients with inflammatory bowel disease (IBD). We evaluated the clinical utility of a novel method to measure serum ATI levels in the presence of infliximab.